Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
Yvonne W WuBryan A ComstockFernando F GonzalezDennis E MayockAmy M GoodmanNathalie L MaitreTaeun ChangKrisa P Van MeursAndrea L LamplandEllen Bendel-StenzelAmit M MathurTai-Wei WuDavid RileyUlrike MietzschLina ChalakJohn FlibotteJoern-Hendrik WeitkampKaashif A AhmadToby D YanowitzMariana BasergaBrenda B PoindexterElizabeth E RogersJean R LoweKarl C K KubanT Michael O'SheaJessica L WisnowskiRobert C McKinstryStefan BlumlSonia BonifacioKristen L BenningerRakesh RaoChristopher D SmyserGregory M SokolStephanie MerharMichael D SchreiberHannah C GlassPatrick J HeagertyChristopher M Traudtnull nullPublished in: The New England journal of medicine (2022)
The administration of erythropoietin to newborns undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy did not result in a lower risk of death or neurodevelopmental impairment than placebo and was associated with a higher rate of serious adverse events. (Funded by the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov number, NCT02811263.).
Keyphrases
- phase iii
- early onset
- pregnant women
- gestational age
- recombinant human
- low birth weight
- cord blood
- cardiac arrest
- atrial fibrillation
- study protocol
- clinical trial
- quality improvement
- brain injury
- phase ii
- cerebral ischemia
- open label
- preterm infants
- double blind
- randomized controlled trial
- congenital heart disease
- placebo controlled
- blood brain barrier